

## Appendix 1.

The California Cancer Registry (CCR) is California's statewide population-based cancer registry, administered by the California Department of Public Health.<sup>1</sup> The California Office of Statewide Health Planning and Development (OSHPD), now known as the Department of Health Care Access and Information, data files include inpatient and ambulatory surgery discharge datasets that are generated via mandated hospital reporting and contain maternal antepartum and postpartum records. The OSHPD does not record data for deliveries that occur at home, out-of-state, in military facilities or at birthing centers that do not report to the OSHPD. The linkage between CCR and OSHPD was conducted by OSHPD following deterministic matching procedures using maternal date of birth, social security number, and ZIP code to establish a linked database with oncologic characteristics and surgical outcomes. This linkage has been used previously to study birth outcomes among women with cancer.<sup>2,3</sup> The linkage between the Society for Assisted Reproductive Technology Clinic Outcome Reporting System (SART-CORS) data set and CCR was accomplished using women's social security number, first and last name, birth date, and infant's birth date when applicable. This linkage has been used previously to study survival outcomes following assisted reproductive technology use after breast cancer.<sup>4</sup>

## REFERENCES

1. California Cancer Registry. About California Cancer Registry. California Cancer Registry. Accessed May 8, 2022. <https://www.ccrca.org/learn-about-ccr/about-cancer-registries/>
2. Nitecki R, Clapp MA, Fu S, et al. Outcomes of the first pregnancy after fertility-sparing surgery for early-stage ovarian cancer. *Obstet Gynecol.* 2021;137(6):1109-1118. doi:10.1097/AOG.0000000000004394
3. Nitecki R, Floyd J, Lamiman K, et al. Outcomes of the first pregnancy after fertility-sparing surgery for early-stage cervical cancer. *Obstet Gynecol.* 2021;138(4):565-573. doi:10.1097/AOG.0000000000004532
4. Rauh-Hain JA, Zubizarreta J, Nitecki R, et al. Survival outcomes following pregnancy or assisted reproductive technologies after breast cancer: A population-based study. *Cancer.* Published online June 29, 2022. doi:10.1002/cncr.34371

Jorgensen K, Meernik C, Wu CF, Murphy CC, Baker VL, Jarmon P, et al. Disparities in fertility-sparing treatment and preservation after a diagnosis of cervical, ovarian, or endometrial cancer. *Obstet Gynecol* 2023;141.

The authors provided this information as a supplement to their article.

©2023 American College of Obstetricians and Gynecologists.

## Appendix 2. Histology Codes Included in Analysis by Cancer Type

Histology	Code*
Cervical	
Adenocarcinoma	8140, 8144, 8380, 8384, 8480-8482
Adenosquamous carcinoma	8560, 8570
Squamous cell carcinoma	8070-8076
None of the above	8000, 8010, 8012, 8015, 8050-8052, 8082-8084, 8098, 8200, 8210, 8245, 8255, 8260, 8261, 8262, 8263, 8310, 8313, 8323 8441, 8460, 8490, 8500
Endometrial	
Adenocarcinoma	8140, 8210, 8570
Endometrioid adenocarcinoma	8380, 8382-8384
Ovarian	
Epithelial	8000, 8010, 8020, 8021, 8033, 8041, 8050, 8070, 8071, 8140, 8144, 8200, 8240, 8243, 8246, 8255, 8260, 8263, 8310, 8313, 8320, 8323, 8330, 8340-8341, 8380, 8383, 8410, 8440, 8441, 8450, 8460, 8461, 8470, 8471, 8480-8482, 8560, 8570, 9014-9015
Germ cell	9060, 9064, 9071, 9080, 9082, 9084-9085, 9090, 9101
Sex cord stromal cell	8590, 8620, 8621-8623, 8631, 8634, 8640, 8650, 8670

\* International Classification of Diseases for Oncology (ICD-O), 3<sup>rd</sup> Edition used<sup>1</sup>

### REFERENCE

1. World Health Organization. *International Classification of Diseases for Oncology (ICD-O)*. 3rd ed., 1st revision. World Health Organization; 2013. Accessed September 25, 2022. <https://apps.who.int/iris/handle/10665/96612>

Jorgensen K, Meernik C, Wu CF, Murphy CC, Baker VL, Jarmon P, et al. Disparities in fertility-sparing treatment and preservation after a diagnosis of cervical, ovarian, or endometrial cancer. *Obstet Gynecol* 2023;141.

The authors provided this information as a supplement to their article.

©2023 American College of Obstetricians and Gynecologists.

**Appendix 3. E-Value of Odds Ratios for Fertility-Sparing Treatment by Cancer Type and Sociodemographic or Clinical Variables**

Sociodemographic or Clinical Variables	Cervical			Endometrial			Ovarian		
	Observed OR	Observed CI limit	Excluded	Observed OR	Observed CI limit	Excluded	Observed OR	Observed CI limit	Excluded
			Null from CI			Null from CI			Null from CI
Age, years									
36-45 vs 18-35	3.40	2.99	*	18.18	9.23	*	5.37	4.59	*
Diagnosis year									
2006-2010 vs 2000-2005	2.44	2.05	*	2.79	1.00	3.12	1.11	1.00	1.68
2011-2015 vs 2000-2005	2.77	2.33	*	2.47	1.00	3.58	1.52	1.00	1.27
SES									
Lower-middle vs lowest	1.46	1.00	1.35	2.01	1.00	2.99	1.36	1.00	1.61
Middle vs lowest	1.58	1.00	1.21	1.49	1.00	6.08	1.98	1.29	*
Upper-middle vs lowest	1.30	1.00	1.50	3.93	1.00	1.52	1.87	1.14	*
Highest vs lowest	1.51	1.00	1.32	3.28	1.00	2.66	2.10	1.38	*
Charlson comorbidity score									
Score $\geq$ 1 vs =0	1.22	1.00	1.59	1.51	1.00	2.88	1.50	1.00	1.41

Jorgensen K, Meernik C, Wu CF, Murphy CC, Baker VL, Jarmon P, et al. Disparities in fertility-sparing treatment and preservation after a diagnosis of cervical, ovarian, or endometrial cancer. *Obstet Gynecol* 2023;141.

The authors provided this information as a supplement to their article.

©2023 American College of Obstetricians and Gynecologists.

Insurance									
Private vs public	1.32	1.00	1.37	1.19	1.00	3.71	1.31	1.00	1.56
Uninsured or self-pay vs public	1.51	1.00	1.75	2.46	1.00	15.26	1.46	1.00	1.94
Marital status									
Married vs single	2.16	1.83	*	2.60	1.00	1.72	1.48	1.00	1.25
Other <sup>†</sup> vs single	1.63	1.00	1.16	2.12	1.000	9.78	1.89	1.00	1.18
Race or ethnicity									
American Indian vs NH White	1.13	1.00	2.73	3.40	1.00	5.37	1.11	1.00	6.56
Asian or Pacific Islander vs NH									
White	1.77	1.30	*	4.43	1.00	1.25	1.54	1.00	1.29
Hispanic vs NH White	1.42	1.00	1.24	2.78	1.00	2.17	1.69	1.15	*
NH Black vs. NH White	1.90	1.07	*	7.23	1.00	1.24	2.37	1.45	*
Rurality									
Urban vs rural	1.16	1.00	1.60	3.60	1.00	1.74	1.61	1.00	1.40
Parity									
1 vs 0	1.24	1.00	1.60	4.62	1.00	41.58	1.53	1.00	1.49
≥2 vs 0	2.36	1.95	*	2.41	1.00	13.41	1.08	1.00	1.77
Cancer stage									

Jorgensen K, Meernik C, Wu CF, Murphy CC, Baker VL, Jarmon P, et al. Disparities in fertility-sparing treatment and preservation after a diagnosis of cervical, ovarian, or endometrial cancer. *Obstet Gynecol* 2023;141.

The authors provided this information as a supplement to their article.

©2023 American College of Obstetricians and Gynecologists.

1B vs 1A	3.59	3.17	*	4.91	1.00	1.48	NA	NA	NA
IC vs IA	NA	NA	NA	NA	NA	NA	1.64	1.20	*
Histology									
Germ cell vs epithelial	NA	NA	NA	NA	NA	NA	2.40	1.86	*
Sex cord stromal vs epithelial	NA	NA	NA	NA	NA	NA	1.96	1.07	*

\*Indicates unable to be calculated as the confidence limit already excluded the null.

†“Other” marital status included separated, divorced, widowed, unmarried, or in a domestic partnership.

Abbreviations: OR, odds ratio; CI, confidence interval; SES, socioeconomic status; NH, non-Hispanic; NA, not applicable